Investment Thesis
Allogene is a pre-commercial biotech company with zero revenue and operating losses of $46.1M, burning $12.9M quarterly with only 2-3 quarters of cash runway remaining. While the balance sheet shows $278.9M equity and $396M assets with minimal debt, the company lacks a visible path to revenue generation and is fundamentally unsustainable without significant external funding or rapid product commercialization.
Strengths
- Strong balance sheet with $278.9M stockholders equity and $396M total assets
- Excellent liquidity position with 9.65x current ratio and zero debt burden
- Sufficient short-term cash runway of $30.3M to continue operations for 2-3 quarters
Risks
- Zero revenue with no commercially approved products indicates pre-clinical development stage with extreme clinical and regulatory risk
- Significant operating losses of $46.1M annually with negative free cash flow of $12.9M is unsustainable without external capital
- Limited cash runway of only 2-3 quarters at current burn rate creates existential refinancing urgency
- Biotech development risk: no guarantee of FDA approval, successful clinical trials, or commercialization success
Key Metrics to Watch
- Cash burn rate and runway extension through financing or revenue
- Clinical trial progression and regulatory milestones toward product approval
- Revenue recognition from any FDA-approved product launches
Financial Metrics
Revenue
0.0
Net Income
-42.6M
EPS (Diluted)
$-0.18
Free Cash Flow
-12.9M
Total Assets
396.0M
Cash
30.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-15.3%
ROA
-10.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
9.65x
Quick Ratio
9.65x
Debt/Equity
0.00x
Debt/Assets
29.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:50:27.583150 |
Data as of: 2026-03-31 |
Powered by Claude AI